Therapy News and Research

RSS

HKUST study suggests innate immune response plays vital role in pathogenesis of AD

Alzheimer's disease (AD) is a devastating condition with no known effective treatment. The disease is characterized by memory loss as well as impaired locomotor ability, reasoning, and judgment. Emerging evidence suggests that the innate immune response plays a major role in the pathogenesis of AD.

7 Jun 2016

Taking hormone therapy drugs for additional five years improves outcomes in breast cancer patients

Breast cancer patients significantly benefit by taking hormone therapy drugs called aromatase inhibitors for an additional five years, according to a major study presented at the Plenary Session of the American Society of Clinical Oncology annual meeting in Chicago and published in the New England Journal of Medicine.

7 Jun 2016

Genes of healthy leanness could lead to new approach to treating obesity-related diabetes

People with type 2 diabetes could be helped by the discovery of a gene linked to leanness.

7 Jun 2016

$One-third of osteoporotic women taking oral bisphosphonates have elevated risk for bone fracture$

One-third of osteoporotic women taking oral bisphosphonates have elevated risk for bone fracture

More than 53 million Americans age 50 and older, primarily women, have osteoporosis or are at high risk for the condition due to low bone density. A recent study of oral bisphosphonates, the most commonly prescribed osteoporosis treatment, found that approximately a third of women prescribed these drugs continue to be at elevated risk for bone fracture, an outcome that may have several origins.

7 Jun 2016

Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the chemotherapy drug methotrexate are more likely to struggle with mental flexibility, organization and related skills as long-term survivors.

7 Jun 2016

Financial pressures prevent access to much-needed care for cancer patients

Financial pressures kept cancer patients from filling prescription medications and attending their doctors' visits, University of North Carolina Lineberger Comprehensive Cancer Center researchers found in a new study.

6 Jun 2016

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

A new University of Leicester study has confirmed the therapeutic potential of bacteriophage combinations to treat highly infectious bacteria C. difficile infections (CDI) while retaining a healthy gut.

6 Jun 2016

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours.

6 Jun 2016

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Empagliflozin has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

6 Jun 2016

Cobimetinib combined with vemurafenib shows added benefit for melanoma with BRAF V600 mutation

Cobimetinib has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation.

6 Jun 2016

New study finds alternative approaches to target proteins sustaining cancer, Alzheimer's disease

Drugs to treat cancer and Alzheimer's disease usually target the active sites of specific protein molecules sustaining the disease. Traditional drug design views proteins as rigid 3-D objects with active sites consisting of surface-accessible "pockets" with a specific, well-defined structure.

6 Jun 2016

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial.

6 Jun 2016

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients.

6 Jun 2016

Targeted therapy rucaparib shows promise in treating pancreatic cancer patients with BRCA mutation

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M. Domchek, MD, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, at the American Society of Clinical Oncology Annual Meeting.

6 Jun 2016

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found.

6 Jun 2016

Novel treatment combination helps combat hard-to-treat pediatric neuroblastoma

For seven months, three-year-old Emil Abbasov underwent chemotherapy to fight the tangerine-sized, cancerous tumor growing in his abdomen. But each time, the tumor resisted harder. Each time, he felt more side effects.

6 Jun 2016

Combination therapy equally good at treating small cell lung cancer

HAVING radiotherapy once a day for six and a half weeks or twice a day for three weeks -- when combined with chemotherapy -- is equally good at treating small cell lung cancer that hasn't spread.

6 Jun 2016

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival.

6 Jun 2016

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial to be presented June 5 at the annual meeting of the American Society for Clinical Oncology.

6 Jun 2016

Therapy News and Research

HKUST study suggests innate immune response plays vital role in pathogenesis of AD

Taking hormone therapy drugs for additional five years improves outcomes in breast cancer patients

Genes of healthy leanness could lead to new approach to treating obesity-related diabetes

One-third of osteoporotic women taking oral bisphosphonates have elevated risk for bone fracture

Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Financial pressures prevent access to much-needed care for cancer patients

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Cobimetinib combined with vemurafenib shows added benefit for melanoma with BRAF V600 mutation

New study finds alternative approaches to target proteins sustaining cancer, Alzheimer's disease

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Targeted therapy rucaparib shows promise in treating pancreatic cancer patients with BRCA mutation

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Novel treatment combination helps combat hard-to-treat pediatric neuroblastoma

Combination therapy equally good at treating small cell lung cancer

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News